A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma
- Conditions
- Lymphoma
- Interventions
- Other: No Intervention
- Registration Number
- NCT04837222
- Lead Sponsor
- Takeda
- Brief Summary
Participants with CD30-positive lympoma will be treated with brentuximab vedotin according to their clinic's standard practice.
The main aim of this study is to collect information on any side effects from treatment with brentuximab vedotin. Other aims are to collect information on how brentuximab vedotin is used to treat these participants and the outcomes of these participants.
- Detailed Description
This is an observational, non-interventional, prospective study in participants with CD30-positive lymphoma who are receiving or will receive the standard treatment of brentuximab vedotin. This study will assess the safety profile and effectiveness of brentuximab vedotin in the real-world clinical practice.
The study will enroll approximately 1000 participants. The data will be collected and recorded in the medical record for the purpose of medical care and also recorded in electronic case report forms (e-CRFs). All the participants will be assigned to a single observational cohort:
• All participants with CD30-positive lymphoma
This multi-center trial will be conducted in China. All participants will be followed up for 24 months unless withdrawal of Informed Consent, lost or death, whichever comes first. The overall duration of the study will be approximately 4 years.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1000
- Undergoing treatment with brentuximab vedotin (of less than 3 months from initial treatment with brentuximab vedotin) or to be received with brentuximab vedotin.
- CD30-positive lymphoma by INV (any CD30 expression)
- Who currently participates in or with plan to participate in any interventional clinical trial.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Participants with CD30-positive Lymphoma No Intervention All participants diagnosed with CD30-positive lymphoma who are receiving or will recieve brentuximab vedotin will be observed prospectively over 24-month period, unless withdrawal of informed consent, lost or death, whichever comes first.
- Primary Outcome Measures
Name Time Method Number of Participants Reporting one or More Serious Adverse Events (SAEs) Up to 4 years
- Secondary Outcome Measures
Name Time Method Duration of Response (DOR) From date of first documented CR until PD (up to 4 years) DOR is calculated from the time of documentation of a CR to documentation of disease progression. CR is defined as disappearance of all residual disease and tumor lesions. Disease progression (PD) is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Progression Free Survival (PFS) Rate 1 year and 2 years PFS rate is calculated as the percentage of participants who reported PFS (at 1st year, 2nd year) as per investigator's assessment after brentuximab vedotin treatment.
Number of Participants Based on Disease Characteristics Up to 4 years Number of participants will be reported based on the type of lymphoma, stage, lines of therapy.
Number of Participants Reporting one or More Adverse Drug Reactions (ADRs) Up to 4 years ADRs refers to AE related to administered drug.
Number of Participants Based on Usage of Brentuximab Vedotin Up to 4 years Number of Cycles of Brentuximub Vedotin Administered in Routine Clinical Practice Up to 4 years Change From Baseline in Quality of Life (QoL) Assessed Using Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym) Questionnaire Version 4 Up to 4 years The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on health related quality of life and contains 42 questions covering health related quality of life, common lymphoma symptoms, and treatment side-effects. It contains four core subscales including: Physical Wellbeing, Social/Family Wellbeing, Emotional Wellbeing, and Functional Wellbeing. All questions are answered on a 5-point likert scale ranging from 0 to 4: 0=not at all,1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. Higher scores are associated with a better quality of life.
Objective Response Rate (ORR) Up to 4 years ORR is defined as the percentage of participants with complete response (CR) and partial response (PR) after treatment in the total number of assessable cases.
Number of Participants With Dose Adjustments During the Study Up to 4 years Cost-effectiveness Ratio Up to 4 years Cost-effectiveness ratio will be assessed by the direct cost (including medication, injunction, test, nursing fee, etc.) under brentuximab vedotin treatment divided by the total percent of CR and PR.
Number of Participants Reporting one or More Adverse Events (AEs) Up to 4 years Time to Next Treatment (TTNT) From start of each line of therapy until next line of therapy (up to 4 years) TTNT is defined as time between start of each line of a therapy to the next line of therapy.
Overall Survival (OS) Rate 1 year and 2 years OS rate is measured as the percentage of participants who reported death (at 1st year, 2nd year) after brentuximab vedotin treatment.
Trial Locations
- Locations (31)
Peking University People's Hospital
🇨🇳Beijing, Beijing, China
The First Affiliated Hospital of Nanchang University
🇨🇳Nanchang, Jiangxi, China
The first hospital of Jilin University
🇨🇳Changchun, Jilin, China
Anhui Provincial Cancer Hospital
🇨🇳Hefei, Anhui, China
Peking University Third Hospita
🇨🇳Beijing, Beijing, China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
🇨🇳Beijing, Beijing, China
The First Affiliated Hospital of Xiamen University
🇨🇳Xiamen, Fujian, China
The First Affiliated Hospital of Guangzhou Medical University
🇨🇳Guangzhou, Guangdong, China
ZhuJiang Hosptital of Southern Medical University
🇨🇳Guangzhou, Guangdong, China
Peking University Shenzhen Hospital
🇨🇳Shenzhen, Guangdong, China
The Fourth Hospital of Hebei Medical University
🇨🇳Shijiazhuang, Hebei, China
HenanProvincial CancerHospital
🇨🇳Zhengzhou, Henan, China
The First Affiliated Hospital of Henan University of Science and Technology
🇨🇳Luoyang, Henan, China
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
🇨🇳Wuhan, Hubei, China
Zhongda Hospital Southeast University
🇨🇳Nanjing, Jiangsu, China
Affiliated Hodpital of Nantong University
🇨🇳Nantong, Jiangsu, China
The First Affiliated Hospital of Soochow University
🇨🇳Suzhou, Jiangsu, China
Jiangsu Province Hospital
🇨🇳Nanjing, Jiangsu, China
The Second Hospital of Dalian Medical University
🇨🇳Dalian, Liaoning, China
Qilu Hospital of Shandong University
🇨🇳Jinan, Shandong, China
ShandongProvincial CancerHospital
🇨🇳Jinan, Shandong, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, Shanghai, China
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
🇨🇳Shanghai, Shanghai, China
West China Hospital of Sichuan University
🇨🇳Chengdu, Sichuan, China
ShanxiProvincial CancerHospital
🇨🇳Taiyuan, Shanxi, China
Hematology Hospital of Chinese Academy of Medical Sciences
🇨🇳Tianjin, Tianjin, China
Tianjin Medical University Cancer Institute & Hospital
🇨🇳Tianjin, Tianjin, China
Yunnan First People's Hospital
🇨🇳Kunming, Yunnan, China
Tianjin People's Hospital
🇨🇳Tianjin, Tianjin, China
The Second Affiliated Hospital Zhejiang University School of Medicine
🇨🇳Hangzhou, Zhejiang, China
The Affiliated People's Hospital of Ningbo University
🇨🇳Ningbo, Zhejiang, China